Cannabinoids as analgesic agents: Evidence from in vivo studies

Current Neuropharmacology

Volumn 2, Issue 1, 2004, Pages 75-89

  Finn, David P ^a   Chapman, Victoria ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cannabinoid receptor; Endocannabinoids; in vivo; Pain; Pre clinical

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL; CALCIUM ION; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DIZOCILPINE; DRONABINOL; DYNORPHIN A; GW 405833; KAPPA OPIATE RECEPTOR; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; O 1057; OLEAMIDE; OPIATE DERIVATIVE; PALMIDROL; POTASSIUM CHANNEL; POTASSIUM ION; PROSTAGLANDIN SYNTHASE INHIBITOR; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; DRUG CLASSIFICATION; DRUG POTENCY; DRUG POTENTIATION; HUMAN; IN VIVO STUDY; MOUSE; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; RAT; REVIEW; SPINAL GANGLION; TAIL FLICK TEST;

EID: 3042566872     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476918     Document Type: Review

References (159)

1. Ahluwalia, J., Urban, L., Bevan, S., Capogna, M., Nagy, I. (2002) Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience, 110, 747-753.
2. Anikwue, R., Huffman, J.W., Martin, Z.L., Welch, S.P. (2002) Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J. Pharmacol. Exp. Ther., 303, 340-346.
3. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
4. Beltramo, M., Piomelli, D. (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport, 11, 1231-1235.
5. Berdyshev, E.V., Boichot, E., Germain, N., Allain, N., Anger, J.P., Lagente, V. (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol., 330, 231-240.
6. Bloom, A.S., Dewey, W.L. (1978) A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl.), 57, 243-248.
7. Bouaboula, M., Poinot-Chazel, C., Bourrie, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Casellas, P. (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J., 312, 637-641.
8. Bridges, D., Ahmad, K., Rice, A.S.C. (2001) The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol., 133, 586-594.
9. Buckley, N.E., McCoy, K.L., Mezey, E., Bonner, T., Zimmer, A., Felder, C.C., Glass, M. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol., 396, 141-149.
10. Burstein, S.H., Rossetti, R.G., Yagen, B., Zurier, R.B. (2000) Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat, 61, 29-41.
11. Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D. (1998) Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
12. Chang, Y.H., Lee, S.T., Lin, W.W. (2001) Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem., 81, 715-723.
13. Chapman, V. (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br. J. Pharmacol., 127, 1765-1767.
14. Chapman, V. (2001) Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology, 41, 870-877.
15. Cichewicz, D.L., Martin, Z.L., Smith, F.L., Welch, S.P. (1999) Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther., 289, 859-867.
16. Clarke, R.W., Harris, J., Jenkins, S., Witton, S.K. (2001) Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit. Neuropharmacology, 40, 570-577.
17. Clayton, N., Marshall, F.H., Bountra, C., O'Shaughnessy, C.T. (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96, 253-260.
18. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Nat. Acad. Sci. USA, 98, 9371-9376.
19. Dajani, E.Z., Larsen, K.R., Taylor, J., Dajani, N.E., Shahwan, T.G., Neeleman, S.D., Taylor, M.S., Dayton, M.T., Mir, G.N. (1999) 1′,1′ -Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J. Pharmacol. Exp. Ther., 291, 31-38.
20. De Petrocellis, L., Melck, D., Bisogno, T., Di Marzo, V. (2000) Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids, 108, 191-209.
21. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J.B., Finazzi-Agro, A., Di Marzo, V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 276, 12856-12863.
22. Desarnaud, F., Cadas, H., Piomelli, D. (1995) Anandamide Amidohydrolase Activity in Rat-Brain Microsomes - Identification and Partial Characterization. J. Biol. Chem., 270, 6030-6035.
23. Deutsch, D.G.,Chin, S.A. (1993) Enzymatic-Synthesis and Degradation of Anandamide, a Cannabinoid Receptor Agonist. Biochem. Pharmacol., 46, 791-796.
24. Deutsch, D.G., Ueda, N., Yamamoto, S. (2002) The fatty acid amide hydrolase (FAAH). Prostaglandins Leukotrienes and Essential Fatty Acids, 66, 201-210.
25. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor [see comments]. Science, 258, 1946-1949.
26. Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L., Pertwee, R., De Petrocellis, L. (1998) Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett., 436, 449-454.
27. Di Matzo, V., Breivogel, C.S., Tao, Q., Bridgen, D.T., Razdan, R.K., Zimmer, A.M., Zimmer, A., Martin, B.R. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
28. Di Marzo, V., Bisogno, T., De Petrocellis, L. (2001) Anandamide: some like it hot. Trends Pharmacol. Sci., 22, 346-349.
29. Di Marzo, V., Bisogno, T., De Petrocellis, L., Brandi, I., Jefferson, R.G., Winckler, R.L., Davis, J.B., Dasse, O., Mahadevan, A., Razdan, R.K., Martin, B.R. (2001) Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun., 281, 444-451.
30. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., Bisogno, T. (2002) Anandamide receptors. Prostaglandins Leukotrienes and Essential Fatty Acids, 66, 377-391.
31. Drew, L.J., Harris, J., Millns, P.J., Kendall, D.A., Chapman, V. (2000) Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur. J. Neurosci., 12, 2079-2086.
32. Egertova, M., Giang, D.K., Cravatt, B.F., Elphick, M.R. (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R. Soc. Lond. B. Biol. Sci., 265, 2081-2085.
33. Ellington, H.C., Cotter, M.A., Cameron, N.E., Ross, R.A. (2002) The effect of cannabinoids on capsaicin-evoked calcitonin gene- related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology, 42, 966-975.
34. Elphick, M.R., Egertova, M. (2001) The neurobiology and evolution of cannabinoid signalling. Philosophical Transactions of the Royal Society of London Series B-Biological Sciences, 356, 381-408.
35. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., Leon, A. (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia, 41, 161-168.
36. Farquhar-Smith, W.P., Egertova, M., Bradbury, E.J., McMahon, S.B., Rice, A.S., Elphick, M.R. (2000) Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell Neurosci., 15, 510-521.
37. Felder, C.C., Nielsen, A., Briley, E.M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D.N., Richardson, J.M., Riggin, R.M., Koppel, G.A., Paul, S.M., Becker, G.W. (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett., 393, 231-235.
38. Ferraro, L., Tomasini, M.C., Cassano, T., Bebe, B.W., Siniscalchi, A., O'Connor, W.T., Magee, P., Tanganelli, S., Cuomo, V., Antonelli, T. (2001) Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J. Neurosci. Res., 66, 298-302.
39. Finn, D.P., Jhaveri, M.D., Beckett, S.R.G., Kendall, D.A., Marsden, C.A., Chapman, V. (2001) The effects of intra-periaqueductal grey administration of the cannabinoid agonist HU210 in a rat model of aversion. Br. J. Pharmacol., 135, 221P.
40. Finn, D.P., Jhaveri, M.D., Beckett, S.R.G., Roe, C.H., Kendall, D.A., Marsden, C.A., Chapman, V. (2003) Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology, 45, 594-604.
41. Fowler, C.J., Boijesson, M., Tiger, G. (2000) Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br. J. Pharmacol., 131, 498-504.
42. Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., James, I. (2001) The role of central and peripheral Cannabinoid(1) receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain, 92, 91-100.
43. Fride, E.,Mechoulam, R. (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol., 231, 313-314.
44. Fride, E. (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins Leukotrienes and Essential Fatty Acids, 66, 221-233.
45. Gardell, L.R., Ossipov, M.H., Vanderah, T.W., Lai, J., Porreca, F. (2002) Dynorphin-independent spinal cannabinoid antinociception. Pain, 100, 243-248.
46. Gauldie, S.D., McQueen, D.S., Pertwee, R., Chessell, I.P. (2001) Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol., 132, 617-621.
47. Glass, M., Dragunow, M., Faull, R.L.M. (1997) Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77, 299-318.
48. Grinspoon, L., Bakalar, J.B. (1993) Marijuana, the forbidden medicine. New Haven, Yale University Press.
49. Guhring, H., Schuster, J., Hamza, M., Ates, M., Kotalla, C.E., Brune, K. (2001) HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur. J. Pharmacol., 429, 127-134.
50. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D.E., Kustanovich, I., Mechoulam, R. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA, 98, 3662-3665.
51. Harris, J., Drew, L.J., Chapman, V. (2000) Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport, 11, 2817-2819.
52. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. (1990) Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA, 87, 1932-1936.
53. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 11, 563-583.
54. Herzberg, U., Eliav, E., Bennett, G.J., Kopin, I.J. (1997) The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett., 221, 157-160.
55. Hohmann, A.G., Martin, W.J., Tsou, K., Walker, J.M. (1995) Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci., 56, 2111-2118.
56. Hohmann, A.G., Herkenham, M. (1998) Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci. Lett., 252, 13-16.
57. Hohmann, A.G., Briley, E.M., Herkenham, M. (1999) Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res., 822, 17-25.
58. Hohmann, A.G., Herkenham, M. (1999) Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience, 92, 1171-1175.
59. Hohmann, A.G., Herkenham, M. (1999) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience, 90, 923-931.
60. Hohmann, A.G., Tsou, K., Walker, J.M. (1999) Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol., 81, 575-583.
61. Holt, S., Nilsson, J., Omeir, R., Tiger, G., Fowler, C.J. (2001) Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br. J. Pharmacol., 133, 513-520.
62. Holt, S., Fowler, C.J. (2003) Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra-but not intracellular pH. Naunyn Schmiedebergs Arch. Pharmacol., 367, 237-244.
63. Howlett, A.C., Song, C., Berglund, B.A., Wilken, G.H., Pigg, J.J. (1998) Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol. Pharmacol., 53, 504-510.
64. Howlett, A.C. (2002) The cannabinoid receptors. Prostaglandins & Other Lipid Mediators, 68-9. 619-631.
65. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
66. Huang, S.M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T.J., Krey, J.F., Chu, C.J., Miller, J.D., Davies, S.N., Geppetti, P., Walker, J.M., Di Marzo, V. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA, 99, 8400-8405.
67. Jaggar, S.I., Hasnie, F.S., Sellaturay, S., Rice, A.S.C. (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76, 189-199.
68. Johanek, L.M., Heitmiller, D.R., Turner, M., Nader, N., Hodges, J., Simone, D.A. (2001) Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain, 93, 303-315.
69. Kelly, S., Chapman, V. (2001) Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J. Neurophysiol., 86, 3061-3064.
70. Kelly, S.,Chapman, V. (2002) Effect of peripheral administration of a selective cannabinoid CB1 receptor agonist on mechanical evoked responses of spinal neurons in carrageenan inflamed rats. 10th World pain Congress. San Diego.
71. Kelly, S., Chapman, V. (2003) Effect of selective activation of spinal CB1 receptors on mechanical evoked responses of spinal neurones in rats with spinal nerve ligation and sham rats. Br. J. Pharmacol.
72. Klein, T.W., Newton, C.A., Friedman, H. (2001) Cannabinoids and the immune system. Pain Res. Manag, 6, 95-101.
73. Kozak, K.R., Rowlinson, S.W., Marnett, L.J. (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem., 275, 33744-33749.
74. Kozak, K.R., Crews, B.C., Morrow, J.D., Wang, L.H., Ma, Y.H., Weinander, R., Jakobsson, P.J., Marnett, L.J. (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem., 277, 44877-44885.
75. Kreitzer, A.C.,Regehr, W.G. (2002) Retrograde signaling by endocannabinoids. Curr. Opin. Neurobiol., 12, 324-330.
76. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Bohme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W., Parmentier, M. (1999) Unresponsiveness to cannabinoids and reduced addicitive effects of opiates in CB1 receptor knockout mice. Science, 283, 401-404.
77. Li, J., Daughters, R.S., Bullis, C., Bergiamin, R., Stucky, M.W., Brennan, J., Simone, D.A. (1999) The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain, 81, 25-33.
78. Lichtman, A.H.,Martin, B.R. (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther., 258, 517-523.
79. Lichtman, A.H., Smith, P.B., Martin, B.R. (1992) The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain, 51, 19-26.
80. Lichtman, A.H., Cook, S.A., Martin, B.R. (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther., 276, 585-593.
81. Lichtman, A.H.,Martin, B.R. (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid- induced antinociception in rats. Pharmacol. Biochem. Behav., 57, 7-12.
82. Lichtman, A.H.,Martin, B.R. (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav., 57, 7-12.
83. Lichtman, A.H., Peart, J., Poklis, J.L., Bridgen, D.T., Razdan, R.K., Wilson, D.M., Poklis, A., Meng, Y., Byron, P.R,, Martin, B.R. (2000) Pharmacological evaluation of aerosolized cannabinoids in mice. Eur. J. Pharmacol., 399, 141-149.
84. Mailleux, P., Parmentier, M., Vanderhaeghen, J.J. (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci. Lett., 143, 200-204.
85. Malan, T.P., Ibrahim, M.M., Deng, H.F., Liu, Q., Mata, H.P., Vanderah, T., Porreca, F., Makriyannis, A. (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 93, 239-245.
86. Malan, T.P., Ibrahim, M.M., Vanderah, T.W., Makriyannis, A., Porreca, F. (2002) Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chemistry and Physics of Lipids, 121, 191-200.
87. Malan, T.P., Ibrahim, M.M., Lai, J., Vanderah, T.W., Makriyannis, A., Porreca, F. (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol., 3, 62-67.
88. Mao, J., Price, D.D., Lu, J., Keniston, L., Mayer, D.J. (2000) Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett., 280, 13-16.
89. Martin, W.J., Hohmann, A.G., Walker, J.M. (1996) Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J . Neurosci., 16, 6601-6611.
90. Martin, W.J., Tsou, K., Walker, J.M. (1998) Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla Neurosci. Lett., 242, 33-36.
91. Martin, W.J., Coffin, P.O., Attias, E., Balinsky, M., Tsou, K., Walker, J.M. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res., 822, 237-242.
92. Martin, W.J., Coffin, P.O., Attias, E., Balinsky, M., Tsou, K., Walker, J.M. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res., 822, 237-242.
93. Martin, W.J., Loo, C.M., Basbaum, A.I. (1999) Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain, 82, 199-205.
94. Mason, D.J. Jr., Lowe, J., Welch, S.P. (1999) Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur. J. Pharmacol., 378, 237-248.
95. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
96. Mechoulam, R.,Gaoni, Y. (1967) Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 86, 1646-1647.
97. Mechoulam, R., Fride, E., Di Matzo, V. (1998) Endocannabinoids. Eur. J. Pharmacol., 359, 1-18.
98. Meng, I.D., Manning, B.H., Martin, W.J., Fields, H.L. (1998) An analgesia circuit activated by cannabinoids. Nature, 395, 381-383.
99. Milligan, E.D., Twining, C., Chacur, M., Biedenkapp, J., O'Connor, K., Poole, S., Tracey, K., Martin, D., Maier, S.F., Watkins, L.R. (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci., 23, 1026-1040.
100. Monhemius, R., Azami, J., Green, D.L., Roberts, M.H.T. (2001) CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res., 908, 67-74.
101. Morisset, V., Ahluwalia, J., Nagy, I., Urban, L. (2001) Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur. J. Pharmacol., 429, 93-100.
102. Morisset, V.,Urban, L. (2001) Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J. Neurophysiol., 86, 40-48.
103. Munro, S., Thomas, K.L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
104. Nackley, A.G., Suplita, R.L., 2nd, Hohmann, A.G. (2003) A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 117, 659-670.
105. Pertwee, R.G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129-180.
106. Pertwee, R.G., Gibson, T.M., Stevenson, L.A., Ross, R.A., Banner, W.K., Saba, B., Razdan, R.K., Martin, B.R. (2000) O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol., 129, 1577-1584.
107. Pertwee, R.G. (2001) Cannabinoid receptors and pain. Prog. Neurobiol., 63, 569-611.
108. Piomelli, D., Giuffrida, A., Calignano, A., Rodriguez de Fonseca, F. (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218-224.
109. Porter, A.C.,Felder, C.C. (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther., 90, 45-60.
110. Porter, A.C., Sauer, J.M., Knierman, M.D., Becker, G.W., Berna, M.J., Bao, J., Nomikos, G.G., Carter, P., Bymaster, F.P., Leese, A.B., Felder, C.C. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
111. Pugh, G., Jr., Smith, P.B., Dombrowski, D.S., Welch, S.P. (1996) The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther., 279, 608-616.
112. Pugh, G. Jr., Mason, D.J. Jr., Combs, V., Welch, S.P. (1997) Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55, 940 in the spinal cord. J. Pharmacol. Exp. Ther., 281, 730-737.
113. Raffa, R.B., Stone, D.J., Jr., Hipp, S.J. (1999) Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. Neurosci. Lett., 263, 29-32.
114. Ralevic, V., Kendall, D.A., Jerman, J.C., Middlemiss, D.N., Smart, D. (2001) Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur. J. Pharmacol., 424, 211-219.
115. Reche, I., Fuentes, J.A., Ruiz-Gayo, M. (1996) Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Eur. J. Pharmacol., 318, 11-16.
116. Reche, I., Ruiz-Gayo, M., Fuentes, J.A. (1998) Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. Neuropharmacology, 37, 215-222.
117. Richardson, J.D., Aanonsen, L., Hargreaves, K.M. (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol., 319, R3-4.
118. Richardson, J.D., Aanonsen, L., Hargreaves, K.M. (1998) Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol., 345, 145-153.
119. Richardson, J.D., Aanonsen, L., Hargreaves, K.M. (1998) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci., 18, 451-457.
120. Richardson, J.D., Kilo, S., Hargreaves, K.M. (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75, 111-119.
121. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
122. Roberts, L.A., Christie, M.J., Connor, M. (2002) Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br. J. Pharmacol., 137, 421-428.
123. Ross, R.A., Coutts, A.A., McFarlane, S.M., Anavi-Goffer, S., Irving, A.J., Pertwee, R.G., MacEwan, D.J., Scott, R.H. (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology, 40, 221-232.
124. Ross, R.A., Gibson, T.M., Brockie, H.C., Leslie, M., Pashmi, G., Craib, S.J., Di Marzo, V., Pertwee, R.G. (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol., 132, 631-640.
125. Salio, C., Fischer, J., Franzoni, M.F., Conrath, M. (2002) Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience, 110, 755-764.
126. Sanudo-Pena, M.C., Strangman, N.M., Mackie, K., Walker, J.M., Tsou, K. (1999) CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Zhongguo Yao Li Xue Bao, 20, 1115-1120.
127. Sharma, S.,Sharma, S.C. (1997) An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J. Ex.p Biol., 35, 1025-1031.
128. Siegling, A., Hofmann, H.A., Denzer, D., Mauler, F., De Vry, J. (2001) Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur. J. Pharmacol., 415, R5-R7.
129. Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers, J.K., Randall, A.D., Davis, J.B. (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227-230.
130. Smith, F.L., Cichewicz, D., Martin, Z.L., Welch, S.P. (1998) The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol. Biochem. Behav., 60, 559-566.
131. Smith, P.B., Martin, B.R. (1992) Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia. Brain Res., 578, 8-12.
132. Sofia, R.D., Vassar, H.B., Knobloch, L.C. (1975) Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia, 40, 285-295.
133. Sokal, D.M., Elmes, S.J.R., Kendall, D.A., Chapman, V. (2003) Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology, 45, 404-411.
134. Stella, N., Schweitzer, P., Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
135. Strangman, N.M., Patrick, S.L., Hohmann, A.G., Tsou, K., Walker, J.M. (1998) Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res., 813, 323-328.
136. Strangman, N.M., Walker, J.M. (1999) Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J. Neurophysiol., 82, 472-477.
137. Thomas, B.F., Wei, X., Martin, B.R. (1992) Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH. J. Pharmacol. Exp. Ther., 263, 1383-1390.
138. Thorat, S.N., Bhargava, H.N. (1994) Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur. J. Pharmacol., 260, 5-13.
139. Tiger, G., Stenstrom, A., Fowler, C.J. (2000) Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. Biochem. Pharmacol., 59, 647-653.
140. Tognetto, M., Amadesi, S., Harrison, S., Creminon, C., Trevisani, M., Carreras, M., Matera, M., Geppetti, P., Bianchi, A. (2001) Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci., 21, 1104-1109.
141. Tsou, K., Lowitz, K.A., Hohmann, A.G., Martin, W.J., Hathaway, C.B., Bereiter, D.A., Walker, J.M. (1996) Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience, 70, 791-798.
142. Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K., Walker, J.M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83, 393-411.
143. Tsou, K., Nogueron, M.I., Muthian, S., Sanudo-Pena, M.C., Hillard, C.J., Deutsch, D.G., Walker, J.M. (1998) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett., 254, 137-140.
144. Vaughan, C.W., Connor, M., Bagley, E.E., Christie, M.J. (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol., 57, 288-295.
145. Wade, D.T., Robson, P., House, H., Makela, P., Aram, J. (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation, 17, 21-29.
146. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., Sanudo-Pena, M.C. (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA, 96, 12198-12203.
147. Walker, J.M., Krey, U., Chu, C.J., Huang, S.M. (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chemistry and Physics of Lipids, 121, 159-172.
148. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 23, 1398-1405.
149. Welch, S.P., Stevens, D.L. (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther., 262, 10-18.
150. Welch, S.P. (1993) Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther., 265, 633-640.
151. Welch, S.P. (1994) Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol. Biochem. Behav., 49, 929-934.
152. Welch, S.P., Dunlow, L.D., Patrick, G.S., Razdan, R.K. (1995) Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther., 273, 1235-1244.
153. Welch, S.P., Thomas, C., Patrick, G.S. (1995) Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther., 272, 310-321.
154. Welch, S.P., Huffman, J.W., Lowe, J. (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther., 287, 1301-1308.
155. Wiley, J.L., Martin, B.R. (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids, 121, 57-63.
156. Wilson, R.I., Nicoll, R.A. (2002) Endocannabinoid signaling in the brain. Science, 296, 678-682.
157. Woolf, C.J.,Mannion, R.J. (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 353, 1959-1964.
158. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M., Bonner, T.I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA, 96, 5780-5785.
159. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D., Hogestatt, E.D. (1999) Vanilloid